A clinical trial involving cosyntropin was updated on September 3, 2026. The trial is titled Polycystic Ovary Syndrome in Type 1 Diabetes and is registered under identifier NCT07490964.
According to the current listing, the trial status is recruiting. No phase information was provided in the record. No results have been posted for this trial at this time.
This update reflects only the recruitment status as listed on the trial registry. No efficacy, safety, or outcome data have been reported for this study. The trial's purpose, as indicated by its title, relates to polycystic ovary syndrome in the context of type 1 diabetes, with cosyntropin as an involved compound in the study.
Readers should note that recruiting status means the trial is currently seeking or enrolling participants, and no conclusions about the compound's effects can be drawn from this stage of the trial. Further updates may be issued as the trial progresses through additional phases or as results become available.
For more background on cosyntropin, including its approved uses and general profile, readers can consult the compound overview.